All In Biotech

Drug Trial Radar · NCT02047994

Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality

Last checked: Nov 19, 2026Latest source record: May 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 30,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

30,000

Planned (sponsor's estimate)

Start

Mar 2013

Primary completion

Dec 2033

Study completion Dec 2035

Sponsor

Lead sponsor
International Agency for Research on CancerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Latvia; Technion, Israel Institute of Technology; Karolinska Institutet; Academic Histology Laboratory (Latvia); Vanderbilt University
First posted
Jan 29, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 40 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Currently no ideal preventive modalities are available for reducing gastric-cancer caused mortality in organized population-based application. The primary objective of the study is to determine if H.pylori screening followed by eradication of positive subjects and endoscopic follow-up of those with serological evidence of atrophic gastritis reduces mortality from gastric cancer in middle-aged people in high-risk areas. The GISTAR study is a multicenter randomized study of H.pylori eradication and pepsinogen testing for prevention of gastric cancer mortality. Altogether 30.000 individuals aged 40-64 years will be enrolled, providing 90% study power to detect at least 35% reduction in gastric cancer mortality at 15 years of follow-up. Participants will be randomly allocated to one of two groups. In the active investigation/management group those positive for H.pylori will be offered eradication therapy and individuals with decreased pepsinogen I/II ratio will be invited for endoscopy. The control group will receive standard health care. The primary endpoint for this trial will be the mortality difference from gastric cancer between the two groups at 15 years or when enough cases accumulate to demonstrate a statistical difference. The study is expected to provide valuable information on the utility for reduction in gastric cancer mortality of: 1) H.pylori eradication in adults on a population-basis, including subjects who may already have pre-malignant lesions; and 2) pepsinogen testing in screening settings. A pilot study of 3,455 individuals prior to the main trial was conducted from October 2013 to December 2016.

Conditions

  • Helicobacter Pylori Infections
  • Atrophic Gastritis
  • Gastric Cancer

Interventions

  • Triple therapyDrug

    Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy. * Esomeprazole 40 mg bid for 10 days * Clarithromycin 500 mg bid for 10 days * Amoxicillin 1000 mg bid for 10 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Gastric cancer mortalityTime frame: 15 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Clinical and Preventive Medicine, University of Latvia

    Riga, Latvia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.